Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EP4 receptor partial agonist for the treatment of pain
摘要:
A novel series of EP4 agonists and antagonists have been identified, and then used to validate their potential in the treatment of inflammatory pain. This paper describes these novel ligands and their activity within a number of pre-chmcal models of pain, ultimately leading to the identification of the EP4 partial agonist GSK726701A. (C) 2018 Elsevier Ltd. All rights reserved.
Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EP4 receptor partial agonist for the treatment of pain
摘要:
A novel series of EP4 agonists and antagonists have been identified, and then used to validate their potential in the treatment of inflammatory pain. This paper describes these novel ligands and their activity within a number of pre-chmcal models of pain, ultimately leading to the identification of the EP4 partial agonist GSK726701A. (C) 2018 Elsevier Ltd. All rights reserved.
BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS
申请人:Giblin Gerald Martin Paul
公开号:US20090318523A1
公开(公告)日:2009-12-24
The present invention relates to benzoisoindole phenylacetic acid derivatives, corresponding pharmaceutical compositions, preparation processes and uses in medicine as EP4 receptor angonists.
[EN] BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS<br/>[FR] DÉRIVÉS DE BENZOISOINDOLE ET UTILISATION DE CEUX-CI EN TANT QU'AGONISTES DU RÉCEPTEUR EP4
申请人:GLAXO GROUP LTD
公开号:WO2008061955A1
公开(公告)日:2008-05-29
[EN] The present invention relates to benzoisoindole phenylacetic acid derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine as EP4 receptor organists. [FR] La présente invention concerne des dérivés de l'acide benzoisoindolephénylacétique, des procédés pour la préparation de ceux-ci, des compositions pharmaceutiques contenant ceux-ci et l'utilisation de ceux-ci en médecine en tant qu'agonistes du récepteur EP4.